To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile MDM2 amp TP53 wild-type
Therapy BI 907828 + Ezabenlimab
Indication/Tumor Type gallbladder adenocarcinoma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
MDM2 amp TP53 wild-type gallbladder adenocarcinoma predicted - sensitive BI 907828 + Ezabenlimab Case Reports/Case Series Actionable In a Phase Ia/Ib trial, treatment with the combination of BI 907828 and Ezabenlimab (BI 754091) resulted in a partial response with a progression-free survival of 7.9 months in a patient with MDM2-amplified (CN=14), TP53 wild-type metastatic gallbladder adenocarcinoma (PMID: 38567193; NCT03964233). 38567193
PubMed Id Reference Title Details
(38567193) Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series. Full reference...